Similar articles

• [ BCG-immunotherapy and bladder cancer].

  Rischmann P. Rischmann P. Prog Urol. 2008 May;18 Suppl 5:S93. doi: 10.1016/S1166-7087(08)72483-7. Prog Urol. 2008. PMID: 18585633 French. No abstract available.
• [Immunotherapy in superficial bladder carcinoma].

  Ríos González E, Martínez-Piñeiro Lorenzo L, Martínez-Piñeiro Caramés JA, de la Peña Barthel JJ. Ríos González E, et al. Arch Esp Urol. 2000 Dec;53(10):879-92. Arch Esp Urol. 2000. PMID: 11213392 Review. Spanish.
• Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors.

  Ibraheim EH, El Kappany H, Nigam VN, Brailovsky CA, Madarnas P, Elhilali MM. Ibraheim EH, et al. Anticancer Res. 1984 May-Jun;4(3):209-13. Anticancer Res. 1984. PMID: 6465859
• [BCG therapy. Its role in the treatment of tumors of the bladder].

  Patard JJ, Chopin DK, Abbou CC. Patard JJ, et al. Ann Urol (Paris). 1995;29(5):292-3. Ann Urol (Paris). 1995. PMID: 8638911 French. No abstract available.
• [The immunotherapy and immunoprophylaxis of bladder cancer].

  Figurin KM, Tsiganu VI. Figurin KM, et al. Urol Nefrol (Mosk). 1993 Jul-Aug;(4):46-9. Urol Nefrol (Mosk). 1993. PMID: 8310570 Review. Russian. No abstract available.